Journal Home
Search for

Volume 15, Issue 5, Pages 626-631 (May 2009)


View previous. 16 of 23 View next.

Risk Factors Affecting Outcome of Second HLA-Matched Sibling Donor Transplantations for Graft Failure in Severe Acquired Aplastic Anemia

John T. Horan1Corresponding Author Informationemail address, Jeanette Carreras2, Sergey Tarima2, Bruce M. Camitta3, Robert Peter Gale4, Gregory A. Hale5, Wolfgang Hinterberger6, Judith Marsh7, Jakob R. Passweg8, Mark C. Walters9, Mary Eapen2

Received 30 October 2008; accepted 31 January 2009.

Abstract 

We examined transplantation outcomes after a second HLA-matched sibling transplantation for primary (16%) or secondary (84%) graft failure in 166 patients with severe acquired aplastic anemia (AA). Two-thirds of these patients has a performance score < 90. In most cases (88%), the same donor was used for both transplants, for both transplantations, and 84% of the second transplantations used bone marrow grafts. We identified 2 prognostic factors: intertransplantation interval (surrogate for primary graft failure and early secondary graft failure) and performance status. Shorter intertransplantation interval (≤ 3 months) and poor performance score (< 90) at second transplantation were associated with high mortality. In patients with a performance score of 90% to 100%, the 8-year probability of overall survival (OS) after second transplantation ≤ 3 and > 3 months from first transplantation was 56% and 76%, respectively. The corresponding probabilities in patients with lower performance scores were 33% and 61%. The predominant cause of failure after second transplantation was nonengraftment (in 72 of 166 patients), most commonly in patients with primary or early secondary graft failure (51 of 72; 71%). Our data indicate that novel approaches, including conditioning regimens with greater immunosuppression, should be explored for these patients.

1 Blood and Marrow Transplant Program, Emory University (Department of Pediatrics)/Children's Healthcare of Atlanta, Atlanta, Georgia

2 Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin

3 Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin

4 Celgene Corporation, Summit, New Jersey

5 St. Jude Children's Research Hospital, Memphis, Tennessee

6 Ludwig Boltzmann Institute, Wien, Austria

7 King's College Hospital, London, UK

8 Geneva University Hospital, Geneva, Switzerland

9 Children's Hospital and Research Center, Oakland, California

Corresponding Author InformationCorrespondence and reprint requests: John T. Horan, MD, MPH, Emory University/Children's Healthcare of Atlanta, Blood and Marrow Transplant Program, 1405 Clifton Road NE, Atlanta, GA 30322.

 Financial disclosure: See Acknowledgments on page 630.

PII: S1083-8791(09)00075-5

doi:10.1016/j.bbmt.2009.01.023


View previous. 16 of 23 View next.